World Investment Advisors Raises Holdings in Cencora, Inc. (NYSE:COR)

World Investment Advisors lifted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,761 shares of the company's stock after acquiring an additional 1,444 shares during the quarter. World Investment Advisors' holdings in Cencora were worth $5,773,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in COR. Fisher Asset Management LLC boosted its position in Cencora by 17.7% during the fourth quarter. Fisher Asset Management LLC now owns 1,091 shares of the company's stock valued at $245,000 after acquiring an additional 164 shares during the last quarter. Jones Financial Companies Lllp boosted its position in shares of Cencora by 212.4% during the 4th quarter. Jones Financial Companies Lllp now owns 2,390 shares of the company's stock valued at $537,000 after purchasing an additional 1,625 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter worth approximately $30,000. Victory Capital Management Inc. increased its holdings in Cencora by 25.2% in the fourth quarter. Victory Capital Management Inc. now owns 255,425 shares of the company's stock worth $57,389,000 after purchasing an additional 51,345 shares in the last quarter. Finally, Assetmark Inc. lifted its stake in Cencora by 1,165.7% in the fourth quarter. Assetmark Inc. now owns 32,097 shares of the company's stock valued at $7,212,000 after buying an additional 29,561 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

COR traded up $6.20 on Monday, hitting $302.43. The company's stock had a trading volume of 1,597,776 shares, compared to its average volume of 1,507,152. The company's 50 day simple moving average is $291.41 and its 200-day simple moving average is $268.32. The firm has a market cap of $58.62 billion, a P/E ratio of 35.08, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01. Cencora, Inc. has a 12 month low of $218.65 and a 12 month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The business had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $3.80 earnings per share. Analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio (DPR) is 25.52%.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the sale, the chairman owned 311,913 shares of the company's stock, valued at $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of Cencora stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer directly owned 47,582 shares in the company, valued at $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,127 shares of company stock worth $9,812,296 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently commented on COR. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a research report on Wednesday, March 12th. Bank of America raised their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. UBS Group boosted their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Robert W. Baird raised their price objective on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Morgan Stanley set a $288.00 price target on shares of Cencora in a research report on Tuesday, April 15th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average target price of $306.33.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.